Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan.
Abu Hejleh T, AlSawalha K, Abdel Hafiz S, Al-Batsh T, Abu Hejleh R, Yaser S, Abu Jazar H, Khader J, Alnsour A, Mohamad I, Abdel Jalil R, Abu-Shanab A, Gharaibeh A, Abu Shattal M, Alibraheem A, Haddad H, Mahmoud N, Obeidat S, Al-Jaghbeer MJ, Furqan M, Cortellini A, Velcheti V, Al-Rabi K. Abu Hejleh T, et al. Among authors: al rabi k. Front Oncol. 2024 Apr 30;14:1369126. doi: 10.3389/fonc.2024.1369126. eCollection 2024. Front Oncol. 2024. PMID: 38746680 Free PMC article.
PET/CT in leukemia: utility and future directions.
Al-Ibraheem A, Allouzi S, Abdlkadir AS, Mikhail-Lette M, Al-Rabi K, Ma'koseh M, Knoll P, Abdelrhman Z, Shahin O, Juweid ME, Paez D, Lopci E. Al-Ibraheem A, et al. Among authors: al rabi k. Nucl Med Commun. 2024 Apr 22. doi: 10.1097/MNM.0000000000001846. Online ahead of print. Nucl Med Commun. 2024. PMID: 38646840
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Campelo RG, Madroszyk A, Mazières J, Curcio H, Wasąg B, Pretzenbacher Y, Grillet F, Dingemans AC, Dziadziuszko R. Remon J, et al. Among authors: al rabi k. J Clin Oncol. 2024 Apr 20;42(12):1350-1356. doi: 10.1200/JCO.23.01521. Epub 2024 Feb 7. J Clin Oncol. 2024. PMID: 38324744
Long-Term Survival Analysis and Prognostic Factors of Arabic Patients with Differentiated Thyroid Carcinoma: A 20-Year Observational Study at the King Hussein Cancer Center (KHCC) Involving 528 Patients.
Al-Ibraheem A, Al-Rasheed U, Mashhadani N, Abdlkadir AS, Al-Adhami DA, Ruzzeh S, Istatieh F, Mansour A, Hamdan B, Kheetan R, Al-Shatti M, Mohamad I, Juweid ME, Abu Sheikha A, Al-Rabi K, Sykiotis GP, Kreissl MC, Ismael T, Sultan I, Abdel-Razeq H. Al-Ibraheem A, et al. Among authors: al rabi k. Cancers (Basel). 2023 Aug 15;15(16):4102. doi: 10.3390/cancers15164102. Cancers (Basel). 2023. PMID: 37627130 Free PMC article.
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Garcia Campelo R, Madroszyk A, Mazières J, Curcio H, Wasąg B, Pretzenbacher Y, Fournier B, Dingemans AC, Dziadziuszko R. Remon J, et al. Among authors: al rabi k. Ann Oncol. 2023 May;34(5):468-476. doi: 10.1016/j.annonc.2023.02.012. Epub 2023 Feb 28. Ann Oncol. 2023. PMID: 36863484 Free article. Clinical Trial.
15 results